Ontology highlight
ABSTRACT: Objective
The aim of this study was to determine the rate of coronavirus disease-19 (COVID-19) among patients with cancer treated with immune checkpoint inhibitors (ICIs).Materials and methods
This was a retrospective study of 1,545 patients with cancer treated with ICIs between July 1, 2019, and February 29, 2020, and 20,418 age-, sex-, and cancer category-matched controls in a large referral hospital system. Confirmed COVID-19 case and mortality data were obtained with Massachusetts Department of Public Health from March 1 through June 19, 2020.Results
The mean age was 66.6 years, and 41.9% were female. There were 22 (1.4%) and 213 (1.0%) COVID-19 cases in the ICI and control groups, respectively. When adjusting for demographics, medical comorbidities, and local infection rates, ICIs did not increase COVID-19 susceptibility.Conclusion
ICIs did not increase the rate of COVID-19. This information may assist patients and their oncologists in decision-making surrounding cancer treatment during this pandemic.
SUBMITTER: Klebanov N
PROVIDER: S-EPMC8100539 | biostudies-literature | 2021 May
REPOSITORIES: biostudies-literature
Klebanov Nikolai N Pahalyants Vartan V Murphy William S WS Theodosakis Nicholas N Zubiri Leyre L Klevens R Monina RM Kwatra Shawn G SG Lilly Evelyn E Reynolds Kerry L KL Semenov Yevgeniy R YR
The oncologist 20210417 5
<h4>Objective</h4>The aim of this study was to determine the rate of coronavirus disease-19 (COVID-19) among patients with cancer treated with immune checkpoint inhibitors (ICIs).<h4>Materials and methods</h4>This was a retrospective study of 1,545 patients with cancer treated with ICIs between July 1, 2019, and February 29, 2020, and 20,418 age-, sex-, and cancer category-matched controls in a large referral hospital system. Confirmed COVID-19 case and mortality data were obtained with Massachu ...[more]